SOX10 and melanoma: Notably, compared to the main effect of immune score only, the multivariable analysis presented an additive interaction of SOX10 with an immune score to predict OS in patients with early-stage (likelihood ratio [LR] test, p = 0.005), but not late-stage melanoma (LR test, p = 0.554) (Fig. 3c, d).